Triazolopyridazine LRRK2 kinase inhibitors

被引：25

作者：

Franzini, Maurizio ^{[1
]}

Ye, Xiaocong M. ^{[1
]}

Adler, Marc ^{[2
]}

Aubele, Danielle L. ^{[1
]}

Garofalo, Albert W. ^{[1
]}

Gauby, Shawn ^{[3
]}

Goldbach, Erich ^{[3
]}

Probst, Gary D. ^{[1
]}

Quinn, Kevin P. ^{[3
]}

Santiago, Pam ^{[3
]}

Sham, Hing L. ^{[1
]}

Tam, Danny ^{[4
]}

Anh Truong ^{[1
]}

Ren, Zhao ^{[4
]}

机构：

[1] Elan Pharmaceut, Dept Med Chem, San Francisco, CA 94080 USA

[2] Elan Pharmaceut, Dept Mol Design, San Francisco, CA 94080 USA

[3] Elan Pharmaceut, Dept Drug Metab & Pharmacokinet, San Francisco, CA 94080 USA

[4] Elan Pharmaceut, Dept Assay Dev, San Francisco, CA 94080 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2013年 / 23卷 / 07期

关键词：

LRRK2; Parkinson's; Inhibition; Kinase; Treatment; Discovery; Wild-type; G2019S mutant; Phosphorylation; SAR; Activity; Selectivity; Bioisostere; Hinge; HTS; Oxidative metabolism; Binding mode; Synthesis; CENTER-DOT-LICL; PARKINSONS-DISEASE; HETEROAROMATICS; AROMATICS; ZINCATION; TARGETS; BINDING;

D O I：

10.1016/j.bmcl.2013.02.043

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Leucine-rich repeat kinase 2 (LRRK2) has been implicated in the pathogenesis of Parkinson's disease (PD). Inhibition of LRRK2 kinase activity is a therapeutic approach that may lead to new treatments for PD. Herein we report the discovery of a series of [1,2,4]triazolo[4,3-b]pyridazines that are potent against both wild-type and mutant LRRK2 kinase activity in biochemical assays and show an unprecedented selectivity towards the G2019S mutant. A structural rational for the observed selectivity is proposed. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：1967 / 1973

页数：7

共 50 条

[1] Exosome markers of LRRK2 kinase inhibition
Wang, Shijie
Kelly, Kaela
Brotchie, Jonathan M.
Koprich, James B.
West, Andrew B.
NPJ PARKINSONS DISEASE, 2020, 6 (01)
[2] Inhibition of LRRK2 or Casein Kinase 1 Results in LRRK2 Protein Destabilization
De Wit, T.
Baekelandt, V.
Lobbestael, E.
MOLECULAR NEUROBIOLOGY, 2019, 56 (08) : 5273 - 5286
[3] Structural Characterization of LRRK2 Inhibitors
Gilsbach, Bernd K.
Messias, Ana C.
Ito, Genta
Sattler, Michael
Alessi, Dario R.
Wittinghofer, Alfred
Kortholt, Arjan
JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (09) : 3751 - 3756
[4] Unlocking the secrets of LRRK2 function with selective kinase inhibitors
Dzamko, Nicolas
Halliday, Glenda M.
FUTURE NEUROLOGY, 2013, 8 (03) : 347 - 357
[5] The LRRK2 signalling system
Price, Alice
Manzoni, Claudia
Cookson, Mark R.
Lewis, Patrick A.
CELL AND TISSUE RESEARCH, 2018, 373 (01) : 39 - 50
[6] Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation
Lobbestael, E.
Civiero, L.
De Wit, T.
Taymans, J. -M.
Greggio, E.
Baekelandt, V.
SCIENTIFIC REPORTS, 2016, 6
[7] Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond
Goering, Stefan
Taymans, Jean-Marc
Baekelandt, Veerle
Schmidt, Boris
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (19) : 4630 - 4637
[8] Novel cinnoline-based inhibitors of LRRK2 kinase activity
Garofalo, Albert W.
Adler, Marc
Aubele, Danielle L.
Bowers, Simeon
Franzini, Maurizio
Goldbach, Erich
Lorentzen, Colin
Neitz, R. Jeffrey
Probst, Gary D.
Quinn, Kevin P.
Santiago, Pam
Sham, Hing L.
Tam, Danny
Truong, Anh P.
Ye, Xiaocong M.
Ren, Zhao
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (01) : 71 - 74
[9] Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity
Fernandez, Belen
Chittoor-Vinod, Vinita G.
Kluss, Jillian H.
Kelly, Kaela
Bryant, Nicole
Nguyen, An Phu Tran
Bukhari, Syed A.
Smith, Nathan
Ordonez, Antonio Jesus Lara
Fdez, Elena
Chartier-Harlin, Marie-Christine
Montine, Thomas J.
Wilson, Mark A.
Moore, Darren J.
West, Andrew B.
Cookson, Mark R.
Nichols, R. Jeremy
Hilfiker, Sabine
JOURNAL OF PARKINSONS DISEASE, 2022, 12 (05) : 1423 - 1447
[10] Inhibition of LRRK2 or Casein Kinase 1 Results in LRRK2 Protein Destabilization
T. De Wit
V. Baekelandt
E. Lobbestael
Molecular Neurobiology, 2019, 56 : 5273 - 5286

← 1 2 3 4 5 →